Impact of copays on vulnerable populations

American Journal of Managed Care

Volumn 12, Issue SUPPL. 13, 2006, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIULCER AGENT; BENZODIAZEPINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PSYCHOTROPIC AGENT;

ASTHMA; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DEPRESSION; DIABETES MELLITUS; DRUG COST; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HYPERTENSION; MEDICAID; MENTAL DISEASE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SEIZURE; VULNERABLE POPULATION; WITHDRAWAL SYNDROME;

COST SHARING; ELIGIBILITY DETERMINATION; HUMANS; MEDICAID; MENTAL DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); UNITED STATES; VULNERABLE POPULATIONS;

EID: 33845265397     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Smith C, Cowan C, Heffler S, Catlin A. National health spending in 2004: recent slowdown led by prescription drug spending. Health Aff (Millwood). 2006;25:186-196.
2. Kaiser Family Foundation. Section 9: prescription drug benefits. In: Employer Health Benefits 2005 Annual Survey. Available at: http://kff.org/ insurance/7315/upload/7315.pdf. Accessed July 31, 2006.
3. Reed MC. An update on Americans' access to prescription drugs. Issue Brief Cent Stud Health Syst Change. 2005:1-4.
4. Kaiser Commission on Medicaid and the Uninsured. (2003a). Access to care for the uninsured: an update. September 2003. Publication No. 4142. Available at: http://www.kff.org/uninsured/4142.cfm. Accessed August 4, 2006.
5. Pomerantz J. Prescription drug copayments and vulnerable populations: problems and opportunities. Presented at: Impact of Prescription Drug Copayments on Vulnerable Populations. Roundtable meeting; June 13, 2006; Philadelphia, Pa.
6. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291:2344-2350.
7. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429.
8. Huskamp HA, Deverka PA, Epstein AM, et al. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children. Arch Gen Psychiatry. 2005;62:435-441.
9. Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care. 2005;43:951-959.
10. Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004;27:384-391.
11. Zeber JE, Copeland LA, Miller AL, Kilbourne AM, Velligan D, Mortensen EM. Ethnicity and the impact of higher medication copayments among veterans with schizophrenia [abstract]. Abstract No. 3029. Health Services Research and Development. National Meeting 2006. Available at: http://www.hsrd.research.va. gov/about/national_meeting/2006/display_abstract.cfm? RecordID=150. Accessed August 3, 2006.
12. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff (Millwood). 2004;23:135-146.
13. Stuart B, Zacker C. Who bears the burden of Medicaid drug copayment policies? Health Aff (Millwood). 1999;18:201-212.
14. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994;331:650-655.
15. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-530.
16. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophrenia Bull. 1995;21:419-429.
17. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv. 2003;54:508-516.
18. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692-699.
19. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143:89-99.
20. The Kaiser Commission on Medicaid and the Uninsured. Implications of the new Medicare law for dual eligibles: 10 key questions and answers. Kaiser Family Foundation. January 9, 2004. Available at: http://www.kff.org/medicaid/4160. cfm. Accessed August 4, 2006.
21. McGuire TG. Outpatient benefits for mental health services in Medicare. Alignment with the private sector? Am Psychol. 1989;44:818-824.
22. Himelhoch S, Weller WE, Wu AW, Anderson GF, Cooper LA. Chronic medical illness, depression, and use of acute medical services among Medicare beneficiaries. Med Care. 2004;42:512-521.
23. Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis. 1999;187:496-502.
24. Koyanagi C. Medicare part D: issues for state agencies. Prescriptions for Progress. 2005;1:10-13. Available at: www.postgradmed.com/pfp/PFP-2.pdf. Accessed August 2, 2006.
25. Bambauer KZ, Sabin JE, Soumerai SB. The exclusion of benzodiazepine coverage in Medicare: simple steps for avoiding a public health crisis. Psychiatr Serv. 2005;56:1143-1146.
26. Surles R. Consequences of and alternatives to impeded access. Presentation at: Impact of Prescription Drug Copayments on Vulnerable Populations. Roundtable meeting; June 13, 2006; Philadelphia, Pa.
27. National Council for Community Behavioral Health. Available at: http://www.nccbh.org/WHO/INDUSTRY/MMA-partD/FormularyQA%20.pdf. Accessed August 2, 2006.
28. Kaiser Family Foundation. The new Medicare prescription drug law: issues for dual eligibles with disabilities and serious conditions. 2004. Available at: http://www.kff.org/medicaid/7119.cfm. Accessed August 3, 2006.
29. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232.
30. Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care. 2006;12:21-28.